M&A
-
Siemens Healthineers buys Aspekt to bolster radiation oncology services
The company’s Varian unit sees Aspekt as complementary to its Advanced Oncology Solutions business, which provides professional and clinical services.
By Nick Paul Taylor • Sept. 27, 2023 -
Enovis inks $847M acquisition to boost orthopedic reconstruction business
A Wells Fargo analyst said the deal was “much larger than what we were expecting.”
By Nick Paul Taylor • Sept. 26, 2023 -
Explore the Trendline➔
Kendall Davis/MedTech Dive, original photos courtesy of Abbott and DexcomTrendlineThe MedTech Dive Outlook on 2021
The pandemic will keep disrupting the industry in the year ahead, as COVID-19 testing wanes and elective procedures slowly ease back. We look at the risks, challenges and opportunities.
By MedTech Dive staff -
Is bigger better? McKinsey predicts the return of large medtech mergers
The analysts argue that pressure to improve margins and become the partner of choice to hospitals favors large deals.
By Nick Paul Taylor • Sept. 22, 2023 -
Boston Scientific to buy back pain treatment company Relievant for $850M
The company, which makes a treatment for chronic back pain, is expected to bring in more than $70 million in sales this year.
By Elise Reuter • Sept. 19, 2023 -
Q&A
Bigfoot CEO talks Abbott acquisition, future of diabetes tech
Jeffrey Brewer hopes to see more integrated solutions for people with diabetes, starting with the company’s partnership with Abbott.
By Elise Reuter • Sept. 15, 2023 -
FTC closes probe of Resonetics’ $900M medical nitinol purchase
The acquisition would give Resonetics a leading supplier of the alloy for the medical device industry.
By Elise Reuter • Sept. 14, 2023 -
Bausch + Lomb seeks funding for $1.75B eye drop acquisition from Novartis
Fitch Ratings called the deal to buy the Xiidra treatment “strategically sound” even as the company’s plan to fund it would increase its leverage.
By Nick Paul Taylor • Sept. 12, 2023 -
Abbott to buy smart insulin pen cap maker Bigfoot
The planned acquisition could shift patients interested in smart pens to Abbott’s Libre CGMs, an analyst wrote.
By Elise Reuter • Sept. 6, 2023 -
Danaher to buy antibody supplier Abcam for $5.7B
The acquisition gives Danaher an entry into the protein consumables market, Stifel analysts said.
By Elise Reuter • Aug. 28, 2023 -
VC funding in medtech ticks up, raising hopes that slump has bottomed
Analysts also forecast renewed interest in M&A now that large companies have worked through a string of spinoffs.
By Nick Paul Taylor • Aug. 25, 2023 -
Agilent to wind down Resolution Bioscience liquid biopsy unit
The company will discontinue operations at the business it bought two years ago for $550 million.
By Susan Kelly • Aug. 21, 2023 -
Bruker to buy PhenomeX and its cell research tools for $108M
The life science tools sector is ripe for consolidation, according to analysts at TD Cowen.
By Susan Kelly • Aug. 18, 2023 -
Labcorp scoops up Tufts Medicine outreach lab, continuing buying spree
As the laboratory services giant continues its acquisition streak, hundreds of employees will be let go at the Boston-based academic health system.
By Susan Kelly • Aug. 15, 2023 -
Cooper scraps $875M takeover of Cook Medical business after FTC investigation
The FTC said ending the planned acquisition “ensures that critical reproductive health markets remain competitive.”
By Nick Paul Taylor • Aug. 2, 2023 -
Baxter progresses with planned kidney care spinoff, expects biopharma solutions sale this quarter
The company expects hospital spending to increase in the second half of the year amid rising procedure volumes and a stabilizing supply chain.
By Elise Reuter • July 27, 2023 -
Teleflex to expand urology portfolio with $600M acquisition
The company reached an agreement to buy Palette Life Sciences, as it looks to grow through acquisitions.
By Elise Reuter • July 26, 2023 -
Big Health buys Limbix to add adolescent depression app to digital therapeutic portfolio
The phone-based treatment, SparkRx, uses self-guided, cognitive behavioral therapy to teach skills such as mood tracking.
By Nick Paul Taylor • July 18, 2023 -
Illumina hit by EU with maximum €432M fine for Grail acquisition
The European Commission called Illumina’s closing of the deal without its approval an “unprecedented” move that undermines its system for regulating the competitive landscape.
By Susan Kelly • July 12, 2023 -
Coloplast to pay $1.2B upfront to buy fish skin wound care business Kerecis
Kerecis’ fish skin biologic, which aids tissue regeneration, helped drive the company’s sales to $74.5 million last year.
By Nick Paul Taylor • July 10, 2023 -
ResMed buys Somnoware to expand sleep management software portfolio
The maker of sleep and respiratory care devices said it plans to retain all of Somnoware’s staff and maintain its open platform for patient testing and treatment.
By Nick Paul Taylor • July 7, 2023 -
Bausch + Lomb bulks up OTC business with J&J deal
The eye care company has become an active acquirer under new CEO Brent Saunders, buying an eye drop product line one week after purchasing several medicines from Novartis.
By Ned Pagliarulo • July 6, 2023 -
Thermo Fisher to buy real-world evidence company CorEvitas for $913M
The acquisition is expected to complement Thermo Fisher’s clinical research business and become “immediately accretive” to its adjusted earnings per share.
By Elise Reuter • July 6, 2023 -
Carol Highsmith. (2005). "The Apex Building" [Photo]. Retrieved from Wikimedia Commons.
FTC proposes updates to merger review that could slow healthcare dealmaking
A new rule proposed by antitrust regulators would ask companies to provide additional information about planned mergers to help the Federal Trade Commission keep pace with increased deal volume and complexity.
By Emily Olsen • June 28, 2023 -
Restor3d inks Conformis buyout, adding hip and knee implants to portfolio
Restor3d, which makes 3D-printed devices for spine, ankle and upper extremity procedures, is buying Conformis at a 96% premium.
By Nick Paul Taylor • June 27, 2023 -
BD plans $540M sale of surgical instrumentation platform to Steris
The divestiture is part of BD’s strategy to simplify its portfolio and focus on higher-growth markets.
By Peter Green • Updated June 20, 2023